7 Recent News and Updates in Lung Cancer

A roundup of some of the latest news and updates for patients with lung cancer from CURE®.

There have been many updates in the field of lung cancer over the past several weeks. Here, CURE® looks back at some of the latest news and updates in lung cancer that patients and survivors may have missed.

  • Keytruda monotherapy continued to significantly improve overall and progression-free survival in patients with previously treated, PD-L1–positive advanced non-small cell lung cancer. READ MORE.
  • Recent study results demonstrated that an at-home prehabilitation program may improve surgical outcomes in patients with lung cancer. READ MORE.
  • Treatment with sotorasib, a KRAS G12C inhibitor, induced rapid responses and encouraging survival outcomes in previously treated patients with KRAS G12C–mutated advanced non–small cell lung cancer. READ MORE.
  • Treatment with Opdivo (nivolumab) plus Yervoy (ipilimumab) and two cycles of platinum doublet chemotherapy in the front-line setting was associated with a significant improvement in overall survival in patients with advanced non-small cell lung cancer, compared to treatment with chemotherapy alone. READ MORE.
  • The International Association for the Study of Lung Cancer recently joined more than 100 cancer centers and organizations in requesting that leading public health officials, President Joseph Biden and other members of the administration prioritize the delivery of a COVID-19 vaccine to cancer survivors and patients receiving active treatment. READ MORE.
  • Findings from a study focused on patient-reported experiences, found that aching joints, aching muscles and fatigue were more common than initially found in clinical trials. READ MORE.
  • Study results demonstrated that the immunotherapy Tecentriq (atezolizumab) plus carboplatin and etoposide safely improved overall survival in patients with extensive-stage small-cell lung cancer. READ MORE.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.